NCT03769415: Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

NCT03769415
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with more than 1 prior line of therapy in the metastatic setting
https://ClinicalTrials.gov/show/NCT03769415

Comments are closed.

Up ↑